```html

Zoster Eye Inflammation (Ocular Herpes Zoster)

What is Zoster eye inflammation?

Zoster eye inflammation, also called ocular herpes zoster or herpes zoster ophthalmicus (HZO), occurs when the varicella‑zoster virus (the same virus that causes chickenpox and shingles) reactivates in the ophthalmic branch of the trigeminal nerve. The virus travels along nerve fibers to structures of the eye and surrounding tissues, producing inflammation that can affect the eyelid, conjunctiva, cornea, sclera, uvea, retina, or optic nerve.

Most often the condition follows a shingles outbreak on the forehead or scalp (the “V1 distribution”). When the skin rash is present along with eye involvement, the infection is considered a medical emergency because irreversible vision loss can occur within days.

According to the CDC and Mayo Clinic, about 10‑20 % of people with facial shingles develop ocular involvement, and the risk rises sharply in adults over 60 years of age.

Common Causes

While the primary trigger is reactivation of dormant varicella‑zoster virus, several factors increase the likelihood of eye inflammation:

• Age ≥ 60 years – immune surveillance declines with age.
• Immunosuppression – HIV infection, organ transplantation, chemotherapy, or long‑term corticosteroids.
• Physical or emotional stress – can impair cellular immunity.
• Recent chickenpox infection – the virus remains latent in dorsal root and cranial nerve ganglia.
• Autoimmune diseases – e.g., rheumatoid arthritis, lupus, which may require immunosuppressive meds.
• Diabetes mellitus – associated with poorer viral control.
• Radiation therapy to the head/neck – can damage ganglionic tissue.
• Severe systemic infection – such as influenza or COVID‑19, that temporarily weakens immunity.
• Trauma to the forehead or eye – may disrupt nerve integrity.
• Vaccination status – lack of prior varicella vaccination or Shingrix® booster.

Associated Symptoms

Ocular herpes zoster presents with a combination of skin, ocular, and systemic signs. Commonly reported symptoms include:

• Prodromal pain or burning on one side of the forehead or eye, often described as “ticking” or “electric shock” sensations.
• Dermatologic rash – grouped vesicles on an erythematous base following the V1 dermatome (forehead, upper eyelid, nose).
• Conjunctival injection – reddening of the white of the eye.
• Keratitis – corneal inflammation causing blurry vision, photophobia, and a gritty feeling.
• Uveitis – inflammation of the iris and ciliary body leading to pain, light sensitivity, and possible pupil irregularities.
• Scleritis or episcleritis – deep or superficial eye redness that may be painful.
• Retinal necrosis – a rare but sight‑threatening complication presenting as floaters or visual field loss.
• Optic neuritis – sudden visual acuity loss and color vision deficits.
• Dry eye or excessive tearing due to involvement of the lacrimal gland.
• Systemic signs – fever, malaise, headache, and sometimes facial palsy (Hutchinson’s sign when the tip of the nose is involved).

When to See a Doctor

Because ocular involvement can progress quickly to permanent vision loss, prompt evaluation is essential. Seek medical care if you experience any of the following:

• Redness, pain, or vision changes that develop within 72 hours of a shingles rash on the forehead or eyelid.
• New‑onset “floaters,” flashes of light, or a shadow/curtain over part of the visual field.
• Severe eye pain that is disproportionate to the visible rash.
• Swelling of the eyelid that interferes with eye opening.
• Persistent fever (>38 °C/100.4 °F) or general feeling of being very unwell.

If you belong to a high‑risk group (elderly, immunocompromised, diabetic), contact your eye‑care provider even sooner—ideally within 24 hours of symptom onset.

Diagnosis

Diagnosis combines clinical observation with targeted investigations:

1. History & Physical Exam – The clinician asks about the rash’s onset, pain pattern, and visual symptoms. A slit‑lamp examination provides magnified view of the cornea, conjunctiva, and anterior chamber.
2. Hutchinson’s sign assessment – Involvement of the tip of the nose strongly predicts ocular disease.
3. Laboratory testing (if uncertain)
   • Polymerase chain reaction (PCR) of vesicular fluid to confirm varicella‑zoster DNA.
   • Direct fluorescent antibody (DFA) staining.
4. Imaging
   • Optical coherence tomography (OCT) to evaluate corneal thickness and retinal layers.
   • Fundus photography or fluorescein angiography if posterior segment (retina/optic nerve) is involved.
5. Baseline visual acuity testing – Gives a reference point for monitoring treatment response.

Most cases are diagnosed clinically; laboratory confirmation is reserved for atypical presentations or immunocompromised patients where the differential includes bacterial keratitis or fungal infection.

Treatment Options

Effective therapy combines antiviral medication, anti‑inflammatory agents, and supportive eye care. Treatment should begin within 72 hours of rash onset for optimal outcomes.

Antiviral Therapy

• Acyclovir 800 mg orally five times daily for 7‑10 days.
• Valacyclovir 1 g orally three times daily (preferred for better bioavailability).
• Famciclovir 500 mg orally three times daily.
• Intravenous acyclovir (10 mg/kg every 8 hours) is reserved for severe ocular disease, immunocompromised patients, or those who cannot tolerate oral meds.

All regimens are supported by the American Academy of Ophthalmology (AAO) and the CDC.

Anti‑Inflammatory & Pain Management

• Topical corticosteroid drops (e.g., prednisolone acetate 1 %) to control anterior segment inflammation, used under close supervision.
• Cycloplegic agents (e.g., cyclopentolate) to relieve ciliary spasm and prevent synechiae.
• Systemic steroids (prednisone 0.5‑1 mg/kg) may be added for severe uveitis or optic neuritis, after antiviral therapy is started.
• Analgesics – acetaminophen or NSAIDs for mild pain; neuropathic agents (gabapentin, pregabalin) for persistent post‑herpetic neuralgia.

Supportive Eye Care

• Lubricating artificial tears every 2‑4 hours to maintain corneal moisture.
• Lubricating ointments at night if there is exposure keratopathy.
• Frequent patching of the affected eye only if advised (to prevent corneal abrasion).
• Monitor intra‑ocular pressure (IOP) if steroid drops are used for more than 2‑3 weeks.

Adjunctive Measures

• Vaccination – Shingrix® (recombinant zoster vaccine) for adults ≥50 years reduces the risk of HZO by ~70 % (CDC, 2023).
• Management of underlying conditions (e.g., tight glucose control in diabetes, adjusting immunosuppressants).
• Follow‑up appointments every 3‑5 days initially, then weekly until the eye is quiescent.

Prevention Tips

Because the virus remains dormant for life, prevention focuses on reducing reactivation risk and early treatment of shingles.

• Get vaccinated – Shingrix® is recommended for adults 50 years and older, even if you’ve previously received Zostavax®.
• Maintain a healthy immune system – balanced diet, regular exercise, adequate sleep, and stress management.
• Control chronic illnesses – keep blood sugar, blood pressure, and cholesterol within target ranges.
• Avoid unnecessary long‑term steroids – discuss tapering plans with your physician.
• Prompt treatment of shingles – if a rash appears on the face or scalp, seek care immediately; antiviral therapy started within 72 hours can prevent ocular spread.
• Good eye hygiene – wash hands frequently, avoid touching the eye, and use clean towels.
• Protect eyes from trauma – wear safety glasses during activities that could injure the eye.

Emergency Warning Signs

Summary

Zoster eye inflammation is a potentially sight‑threatening complication of shingles that affects the ophthalmic branch of the trigeminal nerve. Prompt recognition, rapid antiviral therapy, and careful ophthalmic management dramatically reduce the risk of permanent visual loss. High‑risk individuals—older adults, immunocompromised patients, and those with chronic medical conditions—should be especially vigilant and stay up‑to‑date on the Shingrix® vaccine. When symptoms arise, seeking care within the first 72 hours is crucial, and any sudden worsening of vision or pain warrants immediate emergency evaluation.

For further reading, consult reputable sources such as the Centers for Disease Control and Prevention, Mayo Clinic, National Institutes of Health, and the American Academy of Ophthalmology.

```